Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.48 |
| ▸ | DRD3 | P35462 | 4/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6928842 | 0.86 | DRD2 (0.47) | DRD2DRD3KCNH2HTR1AHTR7 | |
| SCHEMBL6926592 | 0.83 | ADRA1A (0.52) | DRD2DRD3HTR1A | |
| SCHEMBL6926642 | 0.83 | DRD2 (0.46) | DRD2KCNH2 | |
| SCHEMBL6927609 | 0.82 | DRD2 (0.49) | DRD2DRD3KCNH2HTR1AHTR7 | |
| SCHEMBL6922567 | 0.80 | DRD2 (0.42) | DRD2KCNH2 | |
| SCHEMBL6924575 | 0.79 | DRD2 (0.42) | DRD2KCNH2 | |
| SCHEMBL6928543 | 0.78 | DRD2 (0.43) | DRD2DRD3KCNH2HTR1AHTR7 | |
| SCHEMBL6928917 | 0.78 | DRD2 (0.42) | DRD2KCNH2 | |
| SCHEMBL6927067 | 0.77 | DRD2 (0.40) | DRD2KCNH2 | |
| SCHEMBL6928602 | 0.76 | PER2 (0.46) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030120070-A1 | Serotonin 5-HT1A and dopamin D2 receptor ligands | H. LUNDBECK A/S (DE) | 2003-06-26 | — | — | US | disclosed |
| US-6514993-B1 | Useful in the treatment of certain psychic and neurologic disorders | H. LUNDBECK A/S (DK) | 2003-02-04 | — | — | US | disclosed |
| EP-0770066-B1 | SEROTONIN 5-HT 1A AND DOPAMIN D2 RECEPTOR LIGANDS | LUNDBECK & CO AS H (DK) | 2000-05-17 | — | — | EP | disclosed |
| EP-0770066-A1 | SEROTONIN 5-HT 1A AND DOPAMIN D2 RECEPTOR LIGANDS | H. LUNDBECK A/S (DK) | 1997-05-02 | — | — | EP | disclosed |
| WO-1995033729-A1 | SEROTONIN 5-HT1A AND DOPAMIN D2 RECEPTOR LIGANDS | H. LUNDBECK A/S (DK) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120070-A1 | Serotonin 5-HT1A and dopamin D2 receptor ligands | HTR5A, HTR2C, HTR1D | DRD2 7/4885DRD3 17/4885KCNH2 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.